Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838851 · ClinicalTrials.gov registry record · Phase 1
Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00838851 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 26 participants.
The verdict
NCT00838851, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the range of neutrophil response (influx of PMNs to the airways as determined in sputum) after inhalation of CCRE (20,000 EU).
Interventions
- BIOLOGICAL Clinical Center Reference Endotoxin (CCRE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838851
The ClinicalTrials.gov registry entry for NCT00838851 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clinical Center Reference Endotoxin (CCRE) is the first listed.
NCT00838851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838851 about?
NCT00838851 is a clinical study titled "Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults". The purpose of this study is to determine the range of neutrophil response (influx of PMNs to the airways as determined in sputum) after inhalation of CCRE (20,000 EU).
What is the current status of trial NCT00838851?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2003-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00838851?
The interventions under investigation include: Clinical Center Reference Endotoxin (CCRE) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00838851?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.